Newsroom | 30150 results

Sorted by: Latest
Other Science
-

Zef Scientific Retains LCMS Industry Expert to Accelerate Business Expansion

LAKE FOREST, Calif.--(BUSINESS WIRE)--Zef Scientific, Inc. (ZefSci), the leading North America independent service provider of multivendor LCMS systems, today announced a partnership with Boston based Peak Life Science Advisors, LLC with industry expert Rick Carberry. Recently acquired by Shimadzu Scientific Instruments (SSI), ZefSci is looking to help fuel its growth through new partnership development within the LCMS “ecosystem”. Providing expert sales, marketing and in-lab service support fo...
-

Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157

TORONTO--(BUSINESS WIRE)--Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) is pleased to report on the advancement of its patented Quicksome™ sublingual delivery platform as part of the Company’s strategy to position Quicksome™ as a differentiated delivery solution within the evolving compounded peptide marketplace across North and South America. Over the past six months, the Company has expanded its internal formulation capabilities following investments in l...
-

A New Perspective on the Universe, a Breakthrough in Medical Equity: Top Honours at the 2026 Canada-Wide Science Fair

EDMONTON, Alberta--(BUSINESS WIRE)--Youth Science Canada presented the top awards at the 2026 Canada-Wide Science Fair (CWSF) on Thursday evening in Edmonton, Alta....
-

Un nouveau regard sur l'univers, une percée pour l'équité en santé : les grands honneurs de l'Expo-sciences pancanadienne 2026

EDMONTON, Alberta--(BUSINESS WIRE)--Sciences jeunesse Canada a présenté les grands prix de l'Expo-sciences pancanadienne (ESPC) 2026 jeudi soir à Edmonton (Alb.), où 390 finalistes de partout au Canada ont présenté 344 projets et se sont disputé près de 2 millions de dollars en prix, dans le cadre du plus grand événement en STIM pour les jeunes au Canada. Faits saillants : Liam Desre, de Kingston (Ont.), a remporté le Prix du meilleur projet — Découverte pour avoir proposé un nouveau modèle de...
-

PanTher Completes Dose Escalation Phase in Non-Metastatic Pancreatic Cancer Phase 1b Trial and Appoints Tim Clackson to the Board of Directors

AUSTIN, Texas--(BUSINESS WIRE)--PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining early cancer treatment with therapeutic implants administered directly at the tumor site, today announced that it has concluded the dose escalation portion of its Phase 1b clinical trial of PTM-101 in pancreatic ductal adenocarcinoma (PDAC). PanTher has identified the PTM-101 400mg paclitaxel-containing implant as the recommended Phase 2 dose (RP2D) in combination with neoadjuv...
-

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C-mutation and e...
-

Real Chemistry beruft mit Frank Clyburn und Chris Fikry zwei führende Persönlichkeiten der Gesundheitsbranche in das Board of Directors

NEW YORK--(BUSINESS WIRE)--Real Chemistry, ein führender Anbieter von KI-gestützten Erkenntnissen sowie Marketing- und Kommunikationslösungen für den Gesundheits- und Life-Sciences-Sektor, gab heute die Ernennung von zwei nicht geschäftsführenden Board-Mitgliedern bekannt: Frank Clyburn und Christopher (Chris) Fikry, M.D. Mit diesen Ernennungen stärkt das Unternehmen seine Position als führender Partner der weltweit innovativsten Life-Science- und Gesundheitsunternehmen in wichtigen Märkten run...
-

RLS-1496 de Rubedo réduit de 46 % les lésions cutanées précancéreuses liées à la kératose actinique après quatre semaines, avec une irritation minimale, selon les résultats préliminaires d’une étude de phase 1b/2a

SAN FRANCISCO--(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), une société de biotechnologie de phase clinique axée sur l’intelligence artificielle et spécialisée dans les médicaments de rajeunissement cellulaire sélectif ciblant les cellules vieillissantes, a annoncé aujourd’hui les résultats préliminaires d’une étude de phase 1b/2a sur RLS-1496 chez des patients atteints de kératose actinique (AK), une affection courante liée à l’âge entraînant des lésions cutanées précancéreuses, qui s...
-

Rubedos RLS-1496 reduziert in vorläufigen Ergebnissen einer Phase-1b/2a-Studie präkanzeröse Hautläsionen (aktinische Keratosen) nach vier Wochen um 46 % bei minimaler Reizung

SAN FRANCISCO--(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), ein KI-gestütztes Biotech-Unternehmen im klinischen Stadium, das sich auf selektive Medikamente zur Zellverjüngung mit Fokus auf alternde Zellen konzentriert, gab heute vorläufige Ergebnisse einer Phase-1b/2a-Studie mit RLS-1496 bei Patienten mit aktinischer Keratose (AK) bekannt, einer häufigen altersbedingten Erkrankung, die zu präkanzerösen Hautläsionen führt und am häufigsten nach dem 65. Lebensjahr auftritt.1 Die in den V...
-

RLS-1496 da Rubedo reduz lesões pré-cancerígenas de queratose actínica em 46% em quatro semanas com irritação mínima, de acordo com resultados preliminares de um estudo de Fase 1b/2a

SAN FRANCISCO--(BUSINESS WIRE)--A Rubedo Life Sciences, Inc. (Rubedo), uma empresa de biotecnologia em estágio clínico, impulsionada por inteligência artificial e focada em medicamentos seletivos de rejuvenescimento celular direcionados a células envelhecidas, anunciou hoje os resultados preliminares de um estudo de Fase 1b/2a do RLS-1496 em pacientes com queratose actínica (QA), uma condição comum relacionada à idade que resulta em lesões cutâneas pré-cancerígenas, mais comumente observada apó...